Advertisement

A Double-Blind, Placebo-Controlled Study of the Opiate Antagonist, Naltrexone, in the Treatment of Kleptomania

Published:February 13, 2009DOI:https://doi.org/10.1016/j.biopsych.2008.11.022

      Background

      Kleptomania is a rare psychiatric disorder characterized by recurrent stealing and for which there exists no empirically validated treatments. This study examined the efficacy and tolerability of the opioid antagonist naltrexone in adults with kleptomania who have urges to steal.

      Methods

      An 8-week, double-blind, placebo-controlled trial was conducted to evaluate the safety and efficacy of oral naltrexone for kleptomania. Twenty-five individuals with DSM-IV kleptomania were randomized to naltrexone (dosing ranging from 50 mg/day to 150 mg/day) or placebo. Twenty-three subjects (92%) completed the study. Subjects were assessed every 2 weeks with the Yale Brown Obsessive Compulsive Scale Modified for Kleptomania (K-YBOCS), the urge and behavior subscales of the K-YBOCS, the Kleptomania Symptom Assessment Scale (K-SAS), the Clinical Global Impressions Scale (CGI), and measures of depression, anxiety, and psychosocial functioning.

      Results

      Subjects assigned to naltrexone had significantly greater reductions in K-YBOCS total scores (p = .001), stealing urges (p = .032), and stealing behavior (p < .001) compared with subjects on placebo. Subjects assigned to naltrexone also had greater improvement in overall kleptomania severity (reflected in the CGI scores) (p < .001). The mean effective dose of naltrexone was 116.7 (±44.4) mg/day.

      Conclusions

      Naltrexone demonstrated statistically significant reductions in stealing urges and behavior in kleptomania. Naltrexone was well tolerated.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • McElroy S.L.
        • Pope Jr, H.G.
        • Hudson J.I.
        • Keck Jr, P.E.
        • White K.L.
        Kleptomania: A report of 20 cases.
        Am J Psychiatry. 1991; 148: 652-657
        • Aboujaoude E.
        • Gamel N.
        • Koran L.M.
        Overview of kleptomania and phenomenological description of 40 patients.
        Prim Care Companion J Clin Psychiatry. 2004; 6: 244-247
        • Goldman M.J.
        Kleptomania: Making sense of the nonsensical.
        Am J Psychiatry. 1991; 148: 986-996
        • Grant J.E.
        • Kim S.W.
        Clinical characteristics and associated psychopathology of 22 patients with kleptomania.
        Compr Psychiatry. 2002; 43: 378-384
        • Grant J.E.
        • Potenza M.N.
        Gender-related differences in individuals seeking treatment for kleptomania.
        CNS Spectr. 2008; 13: 235-245
        • National Association for Shoplifting Prevention
        Shoplifting statistics.
        2006 (Accessed July 25, 2008)
        • Blanco C.
        • Grant J.
        • Petry N.M.
        • Simpson H.B.
        • Alegria A.
        • Liu S.M.
        • Hasin D.
        Prevalence and correlates of shoplifting in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC).
        Am J Psychiatry. 2008; 165: 905-913
        • Odlaug B.L.
        • Grant J.E.
        Prevalence of impulse control disorders in a college sample.
        2008 (Presented at the Annual Meeting of the American Psychiatric Association, May 2008, Washington, DC. NR2-069 [poster])
        • Grant J.E.
        • Levine L.
        • Kim D.
        • Potenza M.N.
        Prevalence of impulse control disorders in adult psychiatric inpatients.
        Am J Psychiatry. 2005; 162: 2184-2188
        • Lejoyeux M.
        • Feuché N.
        • Loi S.
        • Solomon J.
        • Adès J.
        Study of impulse-control disorders among alcohol-dependent patients.
        J Clin Psychiatry. 1999; 60: 302-305
        • Lejoyeux M.
        • Arbaretaz M.
        • McLoughlin M.
        • Adès J.
        Impulse control disorders and depression.
        J Nerv Ment Dis. 2002; 190: 310-314
        • Esquirol E.
        Des Maladies Mentales.
        Bailliere, Paris1838
        • Grant J.E.
        • Odlaug B.L.
        Kleptomania: Clinical characteristics and treatment.
        Rev Bras Psiquiatr. 2008; 30: S11-S15
        • Grant J.E.
        Family history and psychiatric comorbidity in persons with kleptomania.
        Compr Psychiatry. 2003; 44: 437-441
        • Volpicelli J.R.
        • Alterman A.I.
        • Hayashida M.
        • O'Brien C.P.
        Naltrexone in the treatment of alcohol dependence.
        Arch Gen Psychiatry. 1992; 49: 876-880
        • Anton R.F.
        • Moak D.H.
        • Waid L.R.
        • Latham P.K.
        • Malcolm R.J.
        • Dias J.K.
        Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: Results of a placebo-controlled trial.
        Am J Psychiatry. 1999; 156: 1758-1764
        • Martin W.R.
        • Jasinski D.
        • Mansky P.
        Naltrexone, an antagonist for the treatment of heroin dependence.
        Arch Gen Psychiatry. 1973; 23: 784-789
        • Kosten T.R.
        • Kleber H.D.
        • Morgan C.
        Role of opioid antagonists in treating intravenous cocaine abuse.
        Life Sci. 1989; 44: 887-892
        • Ikemoto S.
        • Glazier B.S.
        • Murphy J.M.
        • McBride W.J.
        Role of dopamine D1 and D2 receptors in the nucleus accumbens in mediating reward.
        J Neurosci. 1997; 17: 8580-8587
        • Kim S.W.
        • Grant J.E.
        • Adson D.E.
        • Shin Y.C.
        Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling.
        Biol Psychiatry. 2001; 49: 914-921
        • Mason B.J.
        • Salvato F.R.
        • Williams L.D.
        • Ritvo E.C.
        • Cutler R.B.
        A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence.
        Arch Gen Psychiatry. 1999; 56: 719-724
        • Stewart J.
        Reinstatement of heroin and cocaine self-administration behavior in the rat by intracerebral application of morphine in the ventral tegmental area.
        Pharmacol Biochem Behav. 1984; 20: 917-923
        • Matthews R.T.
        • German D.C.
        Electrophysiological evidence for excitation of rat ventral tegmental area dopamine neurons by morphine.
        Neuroscience. 1984; 11: 617-625
        • Broekkamp C.L.
        • Phillips A.G.
        Facilitation of self-stimulation behavior following intracerebral microinjections of opioids into the ventral tegmental area.
        Pharmacol Biochem Behav. 1979; 11: 289-295
        • Grant J.E.
        • Kim S.W.
        An open label study of naltrexone in the treatment of kleptomania.
        J Clin Psychiatry. 2002; 63: 349-356
        • Koran L.M.
        • Aboujaoude E.N.
        • Gamel N.N.
        Escitalopram treatment of kleptomania: An open-label trial followed by double-blind discontinuation.
        J Clin Psychiatry. 2007; 68: 422-427
        • Matthews R.T.
        • German D.C.
        Electrophysiological evidence for excitation of rat ventral tegmental area and dopamine neurons by morphine.
        Neuroscience. 1984; 11: 617-625
        • Stewart J.
        Reinstatement of heroin and cocaine self-administration behavior in the rat by intracerebral application of morphine in the ventral tegmental area.
        Pharmacol Biochem Behav. 1984; 20: 917-923
        • Grant J.E.
        • Kim S.W.
        • McCabe J.
        Structured Clinical Interview for Kleptomania (SCI-K): Peliminary validity and reliability testing.
        Int J Methods Psychiatr Res. 2006; 15: 83-94
        • Hamilton M.
        A rating scale for depression.
        J Neurol Neurosurg Psychiatry. 1960; 23: 56-62
        • Hamilton M.
        The assessment of anxiety states by rating.
        Br J Med Psychol. 1959; 32: 50-55
        • First M.B.
        • Spitzer R.L.
        • Gibbon M.
        • Williams J.B.W.
        Structured Clinical Interview for DSM-IV-Patient Edition.
        Biometrics Research Department, New York State Psychiatric Institute (SCID-I/P, Version 2.0), New York1995
        • Sheehan D.V.
        The Anxiety Disease.
        Scribner's, New York1983
        • Kim S.W.
        Opioid antagonists in the treatment of impulse-control disorders.
        J Clin Psychiatry. 1998; 59: 159-164
        • Grant J.E.
        • Kim S.W.
        • Hartman B.K.
        A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges.
        J Clin Psychiatry. 2008; 69: 783-789
        • Guy W.
        ECDEU Assessment Manual for Psychopharmacology.
        National Institute of Mental Health. U.S. Dept Health, Education and Welfare publication (ADM), Rockville, Maryland1976 (76–338, 218–222)
        • Davison A.C.
        • Hinkley D.V.
        Bootstrap Methods and Their Application.
        Cambridge University Press, Cambridge, United Kingdom1997
        • Grant J.E.
        • Potenza M.N.
        • Hollander E.
        • Cunningham-Williams R.
        • Nurminen T.
        • Smits G.
        • Kallio A.
        Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling.
        Am J Psychiatry. 2006; 163: 303-312
        • Mason B.J.
        • Salvato F.R.
        • Williams L.D.
        • Ritvo E.C.
        • Cutler R.B.
        A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence.
        Arch Gen Psychiatry. 1999; 56: 719-724
        • Anton R.F.
        • O'Malley S.S.
        • Ciraulo C.C.
        • Cisler R.A.
        • Couper D.
        • Donovan D.M.
        • et al.
        • COMBINE Study Research Group
        Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial.
        JAMA. 2006; 295: 2003-2017
        • Potenza M.N.
        Should addictive disorders include non-substance-related conditions?.
        Addiction. 2006; 101: 142-151
        • Srisurapanont M.
        • Jarusuraisin N.
        Naltrexone for the treatment of alcoholism: A meta-analysis of randomized controlled trials.
        Int J Neuropsychopharmacol. 2005; 8: 267-280
        • Grant J.E.
        Outcome study of kleptomania patients treated with naltrexone: A chart review.
        Clin Neuropharmacol. 2005; 28: 11-14
        • Dannon P.N.
        • Lowengrub K.M.
        • Iancu I.
        • Kotler M.
        Kleptomania: Comorbid psychiatric diagnosis in patients and their families.
        Psychopathology. 2004; 37: 76-80